effector.jpg
eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination with Checkpoint Inhibitors to Treat Patients with Insufficient Response to Checkpoint Inhibitors Alone
July 27, 2018 07:30 ET | eFFECTOR Therapeutics
SAN DIEGO, July 27, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
effector.jpg
eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin’s Lymphoma
June 06, 2018 07:30 ET | eFFECTOR Therapeutics
SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
effector.jpg
eFFECTOR Initiates Randomized Dosing in Phase 2 Checkpoint Combination Trial of eFT508 and Avelumab in Colorectal Cancer
May 11, 2018 07:30 ET | eFFECTOR Therapeutics
SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
effector.jpg
eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal Chemistry
April 26, 2018 07:30 ET | eFFECTOR Therapeutics
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that...
effector.jpg
eFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual Meeting
April 16, 2018 08:00 ET | eFFECTOR Therapeutics
SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a...
effector_inline_fullcolor_rgb_300.jpg
Clinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile
December 11, 2017 10:00 ET | eFFECTOR Therapeutics
Preclinical Data Shows Potential of eFT226 in B-cell Malignancies Data to be presented at the ASH 59th Annual Meeting and Exposition SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- eFFECTOR...
eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological Effects
November 10, 2017 10:00 ET | EFFECTOR Therapeutics
SAN DIEGO, Nov. 10, 2017 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a poster...
eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer
October 04, 2017 10:00 ET | EFFECTOR Therapeutics
SAN DIEGO, Oct. 04, 2017 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has...
Commence Bio to Present at 2016 Cell & Gene Meeting on the Mesa
September 28, 2016 12:37 ET | Commence Bio
SPARKS, MD--(Marketwired - September 28, 2016) - Commence Bio, Inc., a biotechnology company focused on developing breakthrough immunotherapies using its proprietary STaRT™ platform, announced today...